-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly: Sofe-M combined with bevacizumab treated ovarian cancer, with an objective response rate of 79%.

Zhitongcaijing·10/24/2026 06:41:02
Listen to the news
Eli Lilly: Sofe-M combined with bevacizumab treated ovarian cancer, with an objective response rate of 79%.